A study to investigate the effect on QTcF of Baxdrostat compared with placebo, using Moxifloxacin as a positive control, in healthy participants

Study identifier:D6970C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-Way Crossover Phase I Thorough QTc Study to Investigate the Effect on QTcF of Single Doses of Baxdrostat Compared with Placebo, Using Open-label Moxifloxacin as a Positive Control, in Healthy Participants

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Baxdrostat, Placebo, Moxifloxacin

Sex

All

Estimated Enrollment

28

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 29 Feb 2024
Estimated Primary Completion Date: 13 May 2024
Estimated Study Completion Date: 13 May 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria